Clinical Trials Logo

Filter by:
NCT ID: NCT02477111 Completed - Clinical trials for Abdominal Aortic Aneurysms

European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms

INSIGHT
Start date: March 30, 2015
Phase:
Study type: Observational

INSIGHT is a postmarket clinical follow-up study in the European Union. The purpose of the study is to continue to evaluate the safety and effectiveness/performance of INCRAFT in subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical practice. Approximately 150 subjects will be enrolled and followed through 5-years post procedure. Up to 25 sites in Europe may participate.

NCT ID: NCT02476968 Completed - Clinical trials for BRCA or HRR+ Mutated Ovarian Cancer Patients

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

ORZORA
Start date: September 28, 2015
Phase: Phase 4
Study type: Interventional

This is a prospective, open-label, single arm, multi-center study to assess the real world clinical effectiveness and safety of olaparib maintenance monotherapy as the capsule formulation (in line with the EU approved prescribing information) and will be conducted in platinum-sensitive relapsed high grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) who carry germline or somatic BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious [known or predicted to be detrimental/lead to loss of function]).

NCT ID: NCT02476084 Completed - Clinical trials for Rheumatoid Arthritis

Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients

BMUS
Start date: October 13, 2014
Phase:
Study type: Observational

The purpose of this study is to determine the kinetics of change in quantitative measures of joint inflammation by state of the art power Doppler vascular imaging and to identify biomarkers in biological samples (synovial biopsies, DNA, RNA, PBMC, serum, plasma, urine and stool samples) from parallel cohorts of RA patients undergoing different treatments. This will be achieved implementing MSUS assessments, standard laboratories techniques (such as ELISAs, gene profiling, transcriptome analysis etc.) and the novel CyTOF™ technology.

NCT ID: NCT02474446 Completed - Vitamin D Status Clinical Trials

Getting Vitamin D Dosing Right

Start date: December 2014
Phase: N/A
Study type: Interventional

The investigators want to make sure that people get the right dose of Vitamin D treatment. They will therefore investigate how skin colour, body mass index, ethnicity, vitamin D binding protein and genetic variation affect the response to a standard course of vitamin D in young adults, as a prelude to further studies in younger children.

NCT ID: NCT02474355 Completed - Lung Cancer Clinical Trials

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

ASTRIS
Start date: September 18, 2015
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.

NCT ID: NCT02474017 Completed - Asthma Clinical Trials

An Open Study to Assess the Robustness of the CRC749 Inhaler

Start date: May 2015
Phase: Phase 1
Study type: Interventional

To confirm the robustness of the CRC749 inhaler.

NCT ID: NCT02473939 Completed - Asthma Clinical Trials

An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The purpose of the study is to Evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of VR942 in healthy subjects (part 1) and repeated doses in mild asthmatics (part 2).

NCT ID: NCT02473835 Completed - Inflammation Clinical Trials

Effects of a Short Term Caloric Restriction on T Cell Activation in Fat

Start date: January 2013
Phase: N/A
Study type: Interventional

Overweight and obesity are major problems and their complications such as cardiovascular disease and type 2 diabetes mellitus pose great burdens on healthcare systems. There is accumulating evidence to support obesity being a chronic inflammatory disorder mediated in part by the expansion of adipose (fat) tissue. In addition to adipocytes (fat cells), adipose tissue contains a whole range of other cell types including some immune (white blood) cells. The relative proportions of immune cell subpopulations and interactions between the different cell types within adipose tissue may be important in the development of type 2 diabetes. Previous research by the investigators has suggested that there may be important differences in the activation status of certain immune cells located in adipose tissue with increased overweight and the production of leptin - an appetite regulating hormone. Properties of adipose tissue and inflammatory cells located within it may therefore be sensitive to changes in our nutritional status. The purpose of the present study is to investigate changes in T cell activation in adipose tissue alongside other immunometabolic properties before and after a short period of dieting compared to changes in blood. Participants will include males aged between 35-55 years old who meet the criteria for inclusion. After taking some preliminary measurements and monitoring of normal daily activities, participants will reduce their calorie intake to 50 % of their normal intake/requirements for 3 consecutive days and will attend 1 session of Laboratory testing before and 1 after this period which will take place in the Physiology Laboratories at the University of Bath. It is hoped that investigating immunometabolic responses within adipose tissue following an acute nutritional challenge will help lead to a better understanding of the development of diseases associated with being overweight and ultimately help in the development of more effective methods for prevention and treatment.

NCT ID: NCT02473627 Completed - Healthy Clinical Trials

A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This is an open-label, cross-over, fixed-sequence study. All subjects will receive the same treatment in two study periods. The study is designed to test whether DS-1971a has any effect on the activity of various enzymes involved in the metabolism of medicines, using test medications. These will be given without and then with DS-1971a to see if DS-1971a has any effect on the blood levels of the test medicines.

NCT ID: NCT02473575 Completed - Running Performance Clinical Trials

Does a Caffeine Gum Improve 5 km Run Performance in a Competition/Field Setting?

Start date: June 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether caffeine gum improves the performance of runners completing free timed mass participation 5 km runs in the United Kingdom (UK)